Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

OYS, Finland Clinical Trials

A listing of OYS, Finland clinical trials actively recruiting patients volunteers.

RESULTS

Found (66) clinical trials

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Risk group stratification: R1/R2 stage I+II: R1: resection status: complete R2: resection status: incomplete, stage I and II R2 III: R 2: resection status: incomplete, stage III and LDH < 2 x ULN (according to local reference value for adults) R3/R4: R3: resection status: incomplete, stage III and LDH 2 ...

Phase

0.0 miles

Learn More »

Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage

- Although it has been poorly investigated, the risk of VTE among patients with acute primary intracerebral hemorrhage is generally believed to be at least as high as among patients with ischemic stroke. - The currently available guidelines state that while low doses of subcutaneous heparin or low-molecular-weight heparin may ...

Phase

0.0 miles

Learn More »

Platelet Transfusion in Acute Intracerebral Hemorrhage

- Hematoma growth is a well-known powerful determinant of mortality and poor outcome after intracerebral hemorrhage. - Some observations suggest that previous use of antiplatelet agents associates with rapid hematoma enlargement and poor outcome after cerebral hemorrhage. - Immediate platelet transfusion for such patients may prevent hematoma growth but also ...

Phase N/A

0.0 miles

Learn More »

Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol

After one month of conventional maintenance therapy (MT) children and adolescents, treated for acute lymphoblastic leukemia on Nordic protocols and with wild type thiopurine methyltransferase (TPMT) are eligible for the study. They will first receive a 12 week phase with normal MT during which time repeated sampling of 6-mercaptopurine (6MP) ...

Phase

0.0 miles

Learn More »

Trial Comparing Treatment Strategies in Dupuytren's Contracture

Dupuytren's contracture (DC) is a fibroproliferative disorder of the palmar fascia, which in time leads to flexion contracture in one or more fingers. Etiology of the disease is still unknown, but it strongly seems that genetic factors play a major role. DC is associated most commonly with Caucasian population groups ...

Phase

0.11 miles

Learn More »

Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute

This study is designed to perform a head-to-head comparison of two synthetic ceramic bone graft substitutes, bioactive glass (BAG) and beta-tricalcium phosphate (TCP), in filling of contained bone defects following surgical evacuation of benign bone tumor or tumor-like conditions. Small metacarpal and phalangeal enchondromas (Stratum I) and large long-bone lesions ...

Phase

0.11 miles

Learn More »

Phase

0.11 miles

Learn More »

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studyng safety and immunogenicity of a meningococcal pentavalent vaccine.

Phase

0.11 miles

Learn More »

A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

This is a randomised, two-arm, multicentre, open-label phase II/III efficacy and safety study of MOR208 in combination with BEN versus RTX in combination with BEN given to adult patients who have relapsed after or are refractory to at least one but no more than three prior systemic therapies and have ...

Phase

0.11 miles

Learn More »

This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to ...

Phase

0.11 miles

Learn More »